ONCOLYTICS BIOTECH-Wert mit Potential
| eröffnet am: | 10.02.13 00:51 von: | Heron |
| neuester Beitrag: | 24.04.21 23:58 von: | Ulrikesbyva |
| Anzahl Beiträge: | 236 | |
| Leser gesamt: | 53364 | |
| davon Heute: | 6 | |
bewertet mit 8 Sternen |
||
|
|
||
10.02.13 00:51
#1
Heron
ONCOLYTICS BIOTECH-Wert mit Potential
Saturday, 9 February 2013
Oncolytics Biotech Rises on Further Cancer Treatment Data
http://nasdaqnewsreports.blogspot.de/2013/02/...rises-on-further.html
Oncolytics Biotech Rises on Further Cancer Treatment Data
http://nasdaqnewsreports.blogspot.de/2013/02/...rises-on-further.html
210 Postings ausgeblendet.
12.03.17 18:00
#220
GaryA
Results 2016
http://markets.businessinsider.com/news/stocks/...-End-Results-456558
Schon gesehen und wie bewertet ihr das Ergebnis?
Ich bleibe investiert.
Schon gesehen und wie bewertet ihr das Ergebnis?
Ich bleibe investiert.
01.04.17 20:43
#224
Mister Smith
neue Nachricht vom 31.3.
http://www.stockhouse.com/news/press-releases/...stically-significant
03.04.17 21:04
#227
Cobra7
coole News
schönes Vol. leider wird das aber abverkauft, da noch das ATM-Programm läuft und KE wird bestimmt kommen.
schöne Gewinne bis jetzt sind es trotzdem, glückwunsch an alle :-)
alles aussem Annual Report
We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the Base Shelf) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the Securities)
On February 25, 2016, we entered into a new ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million.........
During 2016, we sold 3,006,600 common shares for gross proceeds of $1,456,296.
http://www.oncolyticsbiotech.com/wp-content/..._Annual_Report_web.pdf
schöne Gewinne bis jetzt sind es trotzdem, glückwunsch an alle :-)
alles aussem Annual Report
We have no assurances that we will be able to raise additional funds through the sale of our common shares, consequently, we will continue to evaluate all types of financing arrangements. In an effort to be able to evaluate all types of financing arrangements, we maintain a current short form base shelf prospectus (the Base Shelf) that qualifies for distribution of up to $150,000,000 of common shares, subscription receipts, warrants, or units (the Securities)
On February 25, 2016, we entered into a new ATM equity distribution agreement with Canaccord Genuity Inc. acting as our sole agent with an aggregate offering value of up to $4.6 million.........
During 2016, we sold 3,006,600 common shares for gross proceeds of $1,456,296.
http://www.oncolyticsbiotech.com/wp-content/..._Annual_Report_web.pdf
08.05.17 13:55
#230
Cobra7
Zahlen
von freitag
Financial
At March 31, 2017, the Company reported $10.1 million in cash, cash equivalents and short-term investments.
As at May 4, 2017, the Company had an unlimited number of authorized common shares with 121,836,722 common shares issued and outstanding, and 8,032,827 options outstanding (with exercise prices ranging between $0.26 and $6.72 and expiry dates ranging from 2017 to 2027).
http://www.oncolyticsbiotech.com/news/...-2017-first-quarter-results/
Financial
At March 31, 2017, the Company reported $10.1 million in cash, cash equivalents and short-term investments.
As at May 4, 2017, the Company had an unlimited number of authorized common shares with 121,836,722 common shares issued and outstanding, and 8,032,827 options outstanding (with exercise prices ranging between $0.26 and $6.72 and expiry dates ranging from 2017 to 2027).
http://www.oncolyticsbiotech.com/news/...-2017-first-quarter-results/
24.05.17 17:25
#231
Cobra7
Da
Ist die KE doch ;-) wie erwartet
Oncolytics Bio prices equity offering; shares down 19% https://seekingalpha.com/news/3269615?source=ansh $ONCYF
Ist die KE doch ;-) wie erwartet
Oncolytics Bio prices equity offering; shares down 19% https://seekingalpha.com/news/3269615?source=ansh $ONCYF